azurrx biopharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. ms1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with additional early stage research being conducted for the prevention of hospital-acquired infection. the company is headquartered in new york, ny, with scientific operations based in langlade, france.
Company profile
Ticker
ENTO
Exchange
Website
CEO
James Sapirstein
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AzurRx BioPharma, Inc., BioPharma d'Azur, Inc.
SEC CIK
Corporate docs
Subsidiaries
First Wave Bio, Inc. • ImmunogenX, LLC ...
ENTO stock data
Latest filings (excl ownership)
S-3
Shelf registration
31 May 24
DEFA14A
Additional proxy soliciting materials
30 May 24
8-K/A
Financial Statements and Exhibits
30 May 24
8-K
Amendments to Articles of Incorporation or Bylaws
16 May 24
10-Q
2024 Q1
Quarterly report
14 May 24
8-K
Entry into a Material Definitive Agreement
13 May 24
424B5
Prospectus supplement for primary offering
13 May 24
8-K/A
Independent Auditor’s Report
8 May 24
10-K
2023 FY
Annual report
29 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Mar 24
Transcripts
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.45 mm | 3.45 mm | 3.45 mm | 3.45 mm | 3.45 mm | 3.45 mm |
Cash burn (monthly) | 93.29 k | (no burn) | 3.10 mm | 1.75 mm | 1.25 mm | 1.11 mm |
Cash used (since last report) | 191.82 k | n/a | 6.37 mm | 3.60 mm | 2.57 mm | 2.28 mm |
Cash remaining | 3.26 mm | n/a | -2.92 mm | -145.07 k | 885.24 k | 1.18 mm |
Runway (months of cash) | 35.0 | n/a | -0.9 | -0.1 | 0.7 | 1.1 |
Institutional ownership, Q2 2023
1.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 11 |
Opened positions | 5 |
Closed positions | 2 |
Increased positions | 1 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 60.11 mm |
Total shares | 47.45 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 16.48 k | $26.36 mm |
STT State Street | 11.80 k | $18.88 mm |
Acadian Asset Management | 9.89 k | $15.00 k |
Tower Research Capital | 7.65 k | $12.25 mm |
Advisor | 1.00 k | $1.60 mm |
BLK Blackrock | 397.00 | $636.00 k |
FMR | 158.00 | $253.00 k |
UBS UBS Group AG - Registered Shares | 29.00 | $46.00 k |
USB U.S. Bancorp. | 24.00 | $38.00 k |
Kathleen S. Wright Associates | 22.00 | $35.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Romano Sarah | Common Stock | Sell | Dispose S | No | No | 4.2294 | 75 | 317.21 | 19,111 |
1 Apr 24 | Sapirstein James | Common Stock | Sell | Dispose S | No | No | 4.2294 | 174 | 735.92 | 37,105 |
15 Mar 24 | Sapirstein James | Common Stock | Sell | Dispose S | No | No | 4.96 | 1,887 | 9.36 k | 37,279 |
15 Mar 24 | Romano Sarah | Common Stock | Sell | Dispose S | No | No | 4.96 | 1,120 | 5.56 k | 19,186 |
News
First Wave BioPharma Changes Name to Entero Therapeutics, Company Advances Toward Phase 3 Clinical Trial With Lead Asset – Latiglutenase For The Treatment Of Celiac Disease
16 May 24
First Wave BioPharma Announces ~$1.1M Registered Direct Offering Of 366,000 Shares Of Common Stock At A Price Of $2.95/Share, Priced At The Market
10 May 24
HC Wainwright & Co. Reinstates Neutral on First Wave BioPharma
25 Mar 24
Roth MKM Maintains Buy on First Wave BioPharma, Lowers Price Target to $36
15 Mar 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
15 Mar 24
Press releases
Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention
22 May 24
Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference
20 May 24
First Wave BioPharma Changes Name to Entero Therapeutics
16 May 24
First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market
10 May 24
First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase
17 Apr 24